EUVIMEDEUVIMED entdecken
Crossref

Sufficient life expectancy as an eligibility criterion in cancer clinical trials

Nicole D Agaronnik, Lisa I Iezzoni

Cancer Letters · 2024-12 · 607 · 217322

DOI: 10.1016/j.canlet.2024.217322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-12. Verfasst von Nicole D Agaronnik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, United States. Electronic address: Nicole_agaronnik@hms.harvard.edu. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Institute for Quantitative Social Science, Harvard University, Harvard University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Harvard Medical School, United States. Electronic address: Nicole_agaronnik@hms.harvard.edu.
  • Health Policy Research Center-Mongan Institute, Massachusetts General Hospital, United States; Department of Medicine, Harvard Medical School, United States.

Förderung

  • Institute for Quantitative Social Science, Harvard University
  • Harvard University

Zitieren

APA

Agaronnik, N. D., & Iezzoni, L. I. (2024). Sufficient life expectancy as an eligibility criterion in cancer clinical trials. Cancer Letters, 607, 217322. https://doi.org/10.1016/j.canlet.2024.217322

Vancouver

Agaronnik ND, Iezzoni LI. Sufficient life expectancy as an eligibility criterion in cancer clinical trials. Cancer Letters. 2024;607:217322. doi:10.1016/j.canlet.2024.217322

BibTeX
@article{Agaronnik2024,
  author = {Agaronnik, Nicole D and Iezzoni, Lisa I},
  title = {Sufficient life expectancy as an eligibility criterion in cancer clinical trials},
  journal = {Cancer Letters},
  year = {2024},
  volume = {607},
  pages = {217322},
  doi = {10.1016/j.canlet.2024.217322}
}
Kostenlos starten →